amantadine has been researched along with Cognition Disorders in 32 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amantadine was reported to decrease serum alanine aminotransferase and HCV RNA levels in chronic hepatitis C patients who had not respond to interferon, but further experience has produced mixed results." | 9.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "Pilocarpine-induced status epilepticus (SE), which results in the development of spontaneous recurrent seizures (SRSs) activates glutamatergic receptors that contribute to seizure sustenance and neuronal cell death." | 7.91 | Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. ( Mohammad, H; Moien-Afshari, F; Sekar, S; Taghibiglou, C; Wei, Z, 2019) |
| "This case report describes a 15-year-old male patient with spastic diplegic cerebral palsy, Gross Motor Function Classification System Level III, who developed severe new cognitive and motoric impairments after the administration of haloperidol." | 7.79 | Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report. ( Gelfius, CD; Mortimer, D; Potts, MA, 2013) |
| "Amantadine was reported to decrease serum alanine aminotransferase and HCV RNA levels in chronic hepatitis C patients who had not respond to interferon, but further experience has produced mixed results." | 5.09 | Treatment of chronic hepatitis C patients with amantadine. ( Harada, H; Yagura, M, 2001) |
| "Pilocarpine-induced status epilepticus (SE), which results in the development of spontaneous recurrent seizures (SRSs) activates glutamatergic receptors that contribute to seizure sustenance and neuronal cell death." | 3.91 | Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. ( Mohammad, H; Moien-Afshari, F; Sekar, S; Taghibiglou, C; Wei, Z, 2019) |
| "We propose that a combination of levetiracetam and amantadine may provide neuroprotective and neurorestorative properties when administered during a period of hyperpyrexia accompanied by any form of mental status changes, particularly if there is a decline in Glasgow Coma Score." | 3.85 | Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report. ( Akinyemi, A; Michel, G; Sanchez-Gonzalez, MA; Sterkel, S, 2017) |
| "This case report describes a 15-year-old male patient with spastic diplegic cerebral palsy, Gross Motor Function Classification System Level III, who developed severe new cognitive and motoric impairments after the administration of haloperidol." | 3.79 | Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report. ( Gelfius, CD; Mortimer, D; Potts, MA, 2013) |
| " Included were 158 patients with schizophrenia or bipolar disorder and a body mass index (BMI) > or = 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n = 68), sibutramine (n = 42), or amantadine (n = 48)." | 3.75 | Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. ( Heinloth, AN; Hoffmann, VP; Kinon, BJ; Lipkovich, I; McGregor, HS; Stauffer, VL, 2009) |
| "Amantadine 400 mg was administered per day." | 2.71 | Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). ( Butters, M; Dixon, E; Donnell, AJ; Kraus, MF; Marion, D; Smith, GS; Yilong, C, 2005) |
| "Amantadine was found to be well tolerated across the studies." | 2.66 | The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review. ( El Ammar, F; Goldenberg, FD; Kramer, CL; Lazaridis, C; Loggini, A; Mansour, A; Tangonan, R, 2020) |
| " Notably, drug dosage and the measure chosen to assess outcome influenced the probability of finding a treatment benefit." | 2.45 | Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis. ( Mathias, JL; Vink, R; Wheaton, P, 2009) |
| "Optimal management of Parkinson's disease patients requires careful titration of medications, with use of polypharmacy, including levodopa, dopamine agonists, catechol-O-methyltransferase inhibitors, amantadine, and anticholinergics in order to maintain good motor function and quality of life." | 2.41 | Parkinson's disease: medical treatment of moderate to advanced disease. ( Suchowersky, O, 2002) |
| "Other therapies in the early stages of Parkinson's disease may include neuroprotective agents, dopamine agonists, dopamine reuptake inhibitors, anticholinergics and/or amantadine." | 2.39 | Treatment options for early Parkinson's disease. ( Brownlee, HJ; Stacy, M, 1996) |
| " We present the results of our own study on the effect of amantadine sulfate, prescribed in the dosage of 300 mg during 6 months, on cognitive disorders in 25 PD patients." | 1.36 | [The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease]. ( Bel'gusheva, ME; Fedorova, NV; Iablonskaia, AIu, 2010) |
| "Neurobehavioural sequelae of traumatic brain injuries require an appropriate/effective pharmacological response in that they represent an important cause of disability." | 1.35 | Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury. ( Lombardi, F, 2008) |
| "Amantadine is a reasonable option for improving cognition and reducing agitation following a TBI but confirmatory evidence of the efficacy the drug is necessary." | 1.33 | Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? ( Leone, H; Polsonetti, BW, 2005) |
| " In the antipsychotic classification, special attention is given to side effects (extrapyramidal motor signs, tardive dyskinesias, akathisis) and to dosage for the elderly." | 1.25 | Observations on the psychopharmacology of the aged. ( Eisdorfer, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (18.75) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 15 (46.88) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Loggini, A | 1 |
| Tangonan, R | 1 |
| El Ammar, F | 1 |
| Mansour, A | 1 |
| Goldenberg, FD | 1 |
| Kramer, CL | 1 |
| Lazaridis, C | 1 |
| Mohammad, H | 1 |
| Sekar, S | 1 |
| Wei, Z | 1 |
| Moien-Afshari, F | 1 |
| Taghibiglou, C | 1 |
| Mortimer, D | 1 |
| Gelfius, CD | 1 |
| Potts, MA | 1 |
| Zhang, J | 1 |
| Tan, H | 1 |
| Jiang, W | 1 |
| Zuo, Z | 1 |
| Yu, M | 1 |
| Zhang, Y | 1 |
| Chen, X | 1 |
| Zhang, T | 1 |
| Sterkel, S | 1 |
| Akinyemi, A | 1 |
| Sanchez-Gonzalez, MA | 1 |
| Michel, G | 1 |
| Stauffer, VL | 1 |
| Lipkovich, I | 1 |
| Hoffmann, VP | 1 |
| Heinloth, AN | 1 |
| McGregor, HS | 1 |
| Kinon, BJ | 1 |
| Stacy, M | 2 |
| Wheaton, P | 1 |
| Mathias, JL | 1 |
| Vink, R | 1 |
| Iablonskaia, AIu | 1 |
| Fedorova, NV | 1 |
| Bel'gusheva, ME | 1 |
| Meehan, WP | 1 |
| Schmidt, JG | 1 |
| Schneider, WN | 1 |
| Arciniegas, DB | 1 |
| Frey, KL | 1 |
| Anderson, CA | 1 |
| Brousseau, KM | 1 |
| Harris, SN | 1 |
| Leone, H | 1 |
| Polsonetti, BW | 1 |
| Napolitano, E | 1 |
| Elovic, EP | 1 |
| Qureshi, AI | 1 |
| Kraus, MF | 2 |
| Smith, GS | 1 |
| Butters, M | 1 |
| Donnell, AJ | 1 |
| Dixon, E | 1 |
| Yilong, C | 1 |
| Marion, D | 1 |
| Sugden, SG | 1 |
| Kile, SJ | 1 |
| Farrimond, DD | 1 |
| Hilty, DM | 1 |
| Bourgeois, JA | 1 |
| Sakakibara, R | 1 |
| Uchiyama, T | 1 |
| Hattori, T | 1 |
| Rao, V | 1 |
| Handel, S | 1 |
| Vaishnavi, S | 1 |
| Keach, S | 1 |
| Robbins, B | 1 |
| Spiro, J | 1 |
| Ward, J | 1 |
| Berlin, F | 1 |
| Lerner, AJ | 1 |
| Strauss, M | 1 |
| Sami, SA | 1 |
| Lombardi, F | 1 |
| Pirovino, M | 1 |
| Meier, J | 1 |
| Meyer, M | 1 |
| Waldmeier, P | 1 |
| Schmid, M | 1 |
| Brownlee, HJ | 1 |
| Maki, PM | 1 |
| Yagura, M | 1 |
| Harada, H | 1 |
| Suchowersky, O | 1 |
| Eisdorfer, C | 1 |
| Andersson, S | 1 |
| Berstad, J | 1 |
| Finset, A | 1 |
| Grimsmo, J | 1 |
| Diehl, LW | 1 |
| Paini, GP | 1 |
| Passoni, M | 1 |
| Parkes, JD | 1 |
| Baxter, RC | 1 |
| Marsden, CD | 1 |
| Rees, JE | 1 |
| Hartmann-von Monakow, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gut Microbiome and Blood Indices in Patients With AD and Their Spousal Caregivers[NCT05601856] | 104 participants (Anticipated) | Observational | 2022-12-15 | Recruiting | |||
| Evaluation of the Effect of Preoperative Intravenous Amantadine Sulfate on the Postoperative Early Cognitive Functions in a Elderly Patient With Laparoscopic Radical Prostatectomy[NCT03988010] | Phase 4 | 54 participants (Anticipated) | Interventional | 2019-05-01 | Active, not recruiting | ||
| Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury[NCT02383472] | 53 participants (Actual) | Interventional | 2012-09-30 | Completed | |||
| Amantadine for Neuroenhancement in Acute Patients Study - A Prospective Pilot Proof of Concept Phase IIb Study in Intensive and Intermediate Care Unit Patients[NCT05479032] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Evaluation and Diagnosis of Potential Research Subjects With Traumatic Brain Injury (TBI)[NCT01287156] | 1,328 participants (Actual) | Observational | 2013-01-10 | Completed | |||
| Biomarkers-Driven Development of Experimental Therapeutics for Traumatic Brain Injury[NCT01420939] | 19 participants (Actual) | Observational | 2011-07-21 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs color-word interferences, made up of color naming, word reading, and inhibition, is measured in seconds, a smaller number represents a better outcome. Participants were given 90 seconds to complete color naming and word reading and 180 seconds to complete inhibition. D-KEFs trail making test, made up of number sequencing, letter sequencing, and number-letter sequencing, is measured in seconds, a faster speed (lower number) represents a better outcome. Participants were given 150 seconds to complete number and letter sequencing and 240 seconds to complete number-letter sequencing. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Seconds (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D-KEFs Color Naming - 3 Weeks | D-KEFs Color Naming - 6 Weeks | D-KEFs Word Reading - 3 Weeks | D-KEFs Word Reading - 6 Weeks | D-KEFs Inhibition - 3 Weeks | D-KEFs Inhibition - 6 Weeks | D-KEFs Number Sequencing - 3 weeks | D-KEFs Letter Sequencing- 3 weeks | D-KEFs Number-Letter Sequencing- 3 weeks | D-KEFs Number Sequencing - 6 weeks | D-KEFs Letter Sequencing- 6 weeks | D-KEFs Number-Letter Sequencing- 6 weeks | |
| MedX Health Console Model 1100 | 3.27 | 3.76 | 0.95 | 1.71 | 7.64 | 32.62 | -24.45 | -28.41 | 8.00 | 11.33 | 6.86 | 12.95 |
| MedX Health Console Model 1100-placebo | 4.76 | 4.07 | 4.07 | 3.44 | 4.48 | 31.59 | -21.17 | -19.51 | 21.93 | 6.89 | 10.59 | 19.81 |
This measure indicates the mean differences in Delis-Kaplan Executive Function System (D-KEF) tests between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. D-KEFs Verbal Fluency Test, made up of letter fluency and category fluency, is measured by number of responses, a larger number represents a better outcome. Participants were given 60 seconds to complete each fluency test. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | Correct responses (Mean) | |||
|---|---|---|---|---|
| D-KEFs Verbal Fluency- letters 3 weeks | D-KEFs Verbal Fluency- letters 6 weeks | D-KEFs Verbal Fluency- category 3 weeks | D-KEFs Verbal Fluency- category 6 weeks | |
| MedX Health Console Model 1100 | -3.45 | -6.71 | -1.14 | -1.62 |
| MedX Health Console Model 1100-placebo | -6.10 | -9.89 | -0.03 | -2.00 |
The primary outcome is mean difference on composite scores of Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) between entry into the study and completion of treatment (visit 18, week 6) for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 6 week scores. There are 5 composite scores on the ImPACT test; verbal memory, visual memory, visual motor speed, reaction time, and symptom score. The ranges for these subscales are as follows: verbal memory and visual memory: 0-100, visual motor speed: 0-60, reaction time: 0-1.0, and symptom score: 0-132. A higher verbal memory, visual memory, and visual motor speed represent a better outcome, while a lower reaction time and lower symptom score represent a better outcome. (NCT02383472)
Timeframe: From baseline to 6 weeks
| Intervention | Units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Verbal Memory | Visual Memory | Visual Motor Speed | Reaction Time | Symptom Score | |
| MedX Health Console Model 1100 | -0.9 | 3.52 | -2.04 | -0.001 | 10.14 |
| MedX Health Console Model 1100-placebo | -5.78 | -7.26 | -5.15 | 0.030 | 11.44 |
"This measure indicates the mean difference in total cognitive symptom scores between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 weeks scores. The total cognitive symptom scored is a sum of 7 symptom scores from the PCSS; feeling slowed down, feeling like in a fog, don't feel right, difficulty concentrating, difficulty remembering, fatigue or low energy, and confusion. The severity of these symptoms are scored 0-6, 0=none, 6=severe. The range for the total cognitive symptom score is 0-42, a lower score represents a better outcome." (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Sx Score - 3 Weeks | Cognitive Sx Score - 6 Weeks | |
| MedX Health Console Model 1100 | 3.95 | 4.00 |
| MedX Health Console Model 1100-placebo | 1.31 | 5.00 |
This measure indicates the mean differences in total post concussion symptom score (PCSS) between entry into the study and 3 weeks and entry into the study and 6 weeks for both the LED group and the placebo group. The mean difference is calculated by taking the mean of differences of the entry scores minus the 3 week scores and the entry scores minus the 6 week scores. The PCSS is a sum of severity scores from 0-6 (0=none, 6=severe) for 22 individual symptoms, like headache, neck pain, or drowsiness. The range for the PCSS is 0-132, a lower score represents a better outcome. (NCT02383472)
Timeframe: From baseline to 3 weeks and from baseline to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| PCSS Total Score - 3 Weeks | PCSS Total score - 6 Weeks | |
| MedX Health Console Model 1100 | 9.41 | 7.86 |
| MedX Health Console Model 1100-placebo | 7.03 | 14.63 |
8 reviews available for amantadine and Cognition Disorders
| Article | Year |
|---|---|
The role of amantadine in cognitive recovery early after traumatic brain injury: A systematic review.
Topics: Amantadine; Brain Injuries, Traumatic; Cognition Disorders; Humans; Nootropic Agents; Randomized Con | 2020 |
Impact of early pharmacological treatment on cognitive and behavioral outcome after traumatic brain injury in adults: a meta-analysis.
Topics: Adult; Amantadine; Behavior; Brain Injuries; Cognition Disorders; Controlled Clinical Trials as Topi | 2009 |
Medical therapies for concussion.
Topics: Amantadine; Analgesics, Non-Narcotic; Antiparkinson Agents; Athletic Injuries; Brain Concussion; Bra | 2011 |
Pharmacological stimulant treatment of neurocognitive and functional deficits after traumatic and non-traumatic brain injury.
Topics: Amantadine; Animals; Brain Injuries; Bromocriptine; Cognition Disorders; Dextroamphetamine; Humans; | 2005 |
[Drug treatment for geriatric urinary disorders; current concept].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Cholinergic Antagonists; Cognition Disorde | 2006 |
Recognizing apathy in Alzheimer's disease.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Amantadine; Cognition Disorders; Depressive Disorder, M | 2007 |
Treatment options for early Parkinson's disease.
Topics: Algorithms; Amantadine; Antiparkinson Agents; Cholinergic Antagonists; Cognition Disorders; Dopamine | 1996 |
Parkinson's disease: medical treatment of moderate to advanced disease.
Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; | 2002 |
2 trials available for amantadine and Cognition Disorders
22 other studies available for amantadine and Cognition Disorders
| Article | Year |
|---|---|
Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus.
Topics: Amantadine; Animals; Astrocytes; Behavior, Animal; Caspase 3; Cell Survival; Cognition Disorders; Di | 2019 |
Deleterious cognitive and motoric effects of haloperidol in an adolescent with cerebral palsy: a case report.
Topics: Adolescent; Amantadine; Carbidopa; Cerebral Palsy; Cognition Disorders; Dopamine Agonists; Dopamine | 2013 |
Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.
Topics: Amantadine; Animals; Cognition Disorders; Glial Cell Line-Derived Neurotrophic Factor; Hippocampus; | 2014 |
Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.
Topics: Amantadine; Animals; Cognition Disorders; Glial Cell Line-Derived Neurotrophic Factor; Hippocampus; | 2014 |
Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.
Topics: Amantadine; Animals; Cognition Disorders; Glial Cell Line-Derived Neurotrophic Factor; Hippocampus; | 2014 |
Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats.
Topics: Amantadine; Animals; Cognition Disorders; Glial Cell Line-Derived Neurotrophic Factor; Hippocampus; | 2014 |
Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress.
Topics: Amantadine; Animals; Antidepressive Agents; Blotting, Western; CA1 Region, Hippocampal; Cognition; C | 2016 |
Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report.
Topics: Adult; Amantadine; Anticonvulsants; Brain; Brain Injuries; Cognition Disorders; Coma; Dopamine Agent | 2017 |
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.
Topics: Adult; Amantadine; Appetite; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Cyclobutanes; D | 2009 |
Medical treatment of Parkinson disease.
Topics: Amantadine; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cognition Disorders; Corp | 2009 |
[The effect of amantadine sulfate on cognitive disorders in patients with Parkinson's disease].
Topics: Aged; Amantadine; Antiparkinson Agents; Cognition Disorders; Female; Humans; Male; Middle Aged; Neur | 2010 |
Pharmacologic treatment of cognitive deficits and hypersexuality due to "shaken-baby syndrome".
Topics: Adrenergic beta-Antagonists; Amantadine; Child; Child Behavior Disorders; Cognition Disorders; Dopam | 2000 |
Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy.
Topics: Adult; Amantadine; Brain; Brain Injuries; Cognition Disorders; Demyelinating Diseases; Diazepam; Dop | 2004 |
Amantadine for traumatic brain injury: does it improve cognition and reduce agitation?
Topics: Administration, Oral; Adolescent; Adult; Aged; Amantadine; Brain Injuries; Cognition Disorders; Huma | 2005 |
Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury.
Topics: Adult; Aggression; Amantadine; Cognition Disorders; Conduct Disorder; Donepezil; Frontal Lobe; Human | 2006 |
Psychiatric sequelae of traumatic brain injury: a case report.
Topics: Adult; Amantadine; Brain Injuries; Clinical Protocols; Cognition Disorders; Cognitive Behavioral The | 2007 |
Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury.
Topics: Amantadine; Animals; Antidepressive Agents; Antipsychotic Agents; Brain Injuries; Cognition; Cogniti | 2008 |
[Malignant neuroleptics syndrome].
Topics: Adult; Amantadine; Baclofen; Cerebrospinal Fluid; Chromatography, Liquid; Cognition Disorders; Femal | 1984 |
Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review.
Topics: Adult; Amantadine; Brain Injuries; Cognition Disorders; Dopamine Agents; Female; Frontal Lobe; Human | 1997 |
Observations on the psychopharmacology of the aged.
Topics: Aged; Amantadine; Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenone | 1975 |
[Amantadine in cognitive failure in patients with traumatic head injuries].
Topics: Adult; Amantadine; Attention; Brain Injuries; Cognition Disorders; Humans; Male; Middle Aged | 1992 |
["Nil nocere." Side effects during treatment of Parkinson's disease with amantadine].
Topics: Aged; Amantadine; Cognition Disorders; Edema; Eyelids; Female; Fingers; Foot; Hand; Humans; Kidney; | 1972 |
[Results obtained with L-DOPA and amantadine in the treatment of patients with disorders of consciousness and of the vigilant state].
Topics: Adult; Aged; Amantadine; Attention; Brain Diseases; Brain Injuries; Brain Neoplasms; Cognition Disor | 1973 |
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.
Topics: Aged; Amantadine; Cognition Disorders; Dihydroxyphenylalanine; Drug Therapy, Combination; Edema; Eye | 1974 |
[Treatment of the Parkinson syndrome with amantadine].
Topics: Adult; Aged; Amantadine; Arteriosclerosis; Cognition Disorders; Dihydroxyphenylalanine; Drug Interac | 1971 |